graminis Pers.:Pers.) and common root rot [caused primarily by Bipolaris sorokiniana (Sacc. in Sorok.) Shoem.]. The germplasm line has grain yield, days to maturity, test weight, kernel weight, grain protein content, and gluten strength similar to Neepawa and the recurrent parent BW90. P8913-V2A5 is heterogeneous for leaf rust reaction (caused by P. recondita Roberge ex Desmaz.) and, at an average height of 104 cm, is 5 cm shorter than Neepawa. HY358 and HY320, the recurrent parents of P8917-B4D4 and P8921-Q4C5, are high-yielding wheat cultivars with medium protein content, gluten strength, and kernel hardness. P8917-B4D4 is a white-seeded and P8921-Q4C5 is a red-seeded germplasm line. P8917-B4D4 has a resistant reaction to loose smut, a moderately resistant reaction to stem rust and common root rot, and a moderately resistant to moderately susceptible reaction to leaf rust. Apart from test weight similar to Neepawa, P8917-B4D4 has higher grain yield and kernel weight, and requires about 4 d more to mature. Grain protein content is less, and height is 12 cm shorter than Neepawa. P8921-Q4C5 has a resistant reaction to loose smut and is moderately resistant to stem rust and common root rot. Compared with Neepawa, P8921-Q4C5 has similar test weight, greater grain yield, a heavier kernel weight, and more resistance to leaf rust (resistant to moderately resistant); it is about 3 d later to mature. Grain protein content is less and height is 13 cm shorter than Neepawa. Small amounts of seed, as well as more detailed information on the performance of the germplasm lines BW90, HY358, and HY-424, are available from the corresponding author.
BackgroundDiffuse hyperechogenicity of the kidney pyramids, detected by kidney ultrasound (US) scan, has been reported as a frequent finding in severe, untreated, tophaceous gout. It seemed related to crystal deposition in the renal medulla and correlated with kidney function decrease, reviving the concept of gouty microcrystalline nephropathy [1].ObjectivesTo confirm this finding and to detect its progression with gout duration.MethodsPatients fulfilled the ACR/EULAR criteria, were not treated by urate-lowering drugs (ULD) at the time of examination; 44 % had received short courses of ULD in the past. They underwent kidney US scans by an experienced radiologist, who classified each kidney into 3 grades according to the presence and degree of hyperechogenicity of the renal pyramids, as compared to the renal cortex. Grade 0 was defined as no medulla hyperechogenicity; grade 1 by the observation of hyperechogenic spots in 1 or 2 renal pyramids; grade 3 as a diffuse hyperechogenicity of at least 3 pyramids (out of 5 scanned). Demographic variables, comorbidities, gout and biochemical features were retrieved from electronic files. US scans of the MTP joints allowed gradation of double contours from 0 to 3. Links between patients ‘features and renal medulla staging were assessed by Fisher exact or Kruskall and Wallis tests according to the type of variables. Multivariable analysis included all statistically significant features, with model selection on p.value using a proportional odds logistic regression model. All test were two-sided.Results826 consecutive new patients were included from August 1 to December 24, 2022. 88 % were males, median age was 49 years, median BMI 24.22 kg/m2, median gout duration 5 years, 70 % of patients had clinical tophi, median uricemia was 488,6 µmol/l, median creatininemia 83.5 mmol/l, median eGFR 93 ml/min. Both kidneys were classified at the same grade in every all patients. 65.5% of patients were at grade 0, 17.8 % at grade 1 and 16.7 % at grade 3. Table 1 shows links of the extent of medulla hyperechogenicity with patients ‘features. By multivariable analysis, positive correlation was found with male sex, hypertension, gout duration, tophi, double contours and uricemia; BMI, eGFR and cortilsolemia negatively correlated.ConclusionHyperechogenicity of the renal medullas progressively increased with gout duration, MSU deposition and steroid treatment, and associated with decrease of renal function and hypertension. These observations reinforce the early indication of ULDs in gouty patients.Reference[1]Bardin T et al. Kidney Intern 2021;99: 218–226Table 1.Main features of gouty patients by grades of medulla hyperechogenicityGrade 0n = 541Grade 1n = 147Grade 2n = 138p valuep.value MultiAge (y) median [IQR]47 [38, 56]51 [44, 59]54 [45, 62]<0.001Males n (%)441 (81.7)147 (100.0)138 (100)<0.001<0.001BMI (kg/m2) median [IQR]24.4 [22.5, 26.7]24.1 [22.5, 26.1]23.3 [21.2, 25.8]0.003<0.001Hypertension n (%)145 (26.8)54 (36.7)88 (63.8)<0.0010.006CHD n (%)6 (1.1)7 (4.8)7 (5.1)0.003Type 2 diabetes n (%)62 (11.5)17 (11.6)27 (19.6)0.04Gout duration (y) median [IQR]4 [2, 7]7 [4, 11]11 [8, 17]<0.001<0.001Tophi n (%)298 (55.1)14 (95.9)137 (99.3)<0.001<0.001Urinary stone n (%)23 (4.3)18 (12.2)13 (9.4)0.001SUA (umol/l) median [IQR]437 [322, 548]533 [432, 602]558 [493, 618]<0.001<0.001Creatininemia (mmol/l) median [IQR]81 [67, 92]87 [76, 106]93 [79, 107]<0.001eGFR > 60 ml/min n (%)506 (93.5)128 (87.1)112 (81.2)<0.001Maximum double contours<0.001<0.001 0 n (%)17 (34.1)0 (0.0)0 (0.0) Thin n (%)86 (20.7)8 (5.4)1 (0.7) Medium n (%)306 (73.6)114 (77.6)66 (47.8) Thick n (%)7 (1.7)25 (17.0)71 (51.4)8 am cortisol median [IQR]7.55 [3.58,10.33]6.60 [1.95,10.72]1.91 [0,59,8.06]<0.0010.005y: years; IQR: interquartile range; BMI: body mass index; CHD: coronary heart disease; eGFR estimated glomerular filtration rate (MDRD)Acknowledgements:NIL.Disclosure of InterestsNone Declared.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.